Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the efficacy of fulvestrant 500 mg treatment with fulvestrant 250 mg treatment in terms of time to progression (TTP)
Critère d'inclusion
- Postmenopausal women with advanced breast cancer, progressing or relapsing after previous endocrine therapy